Minimal residual disease monitoring by RQ-PCR of Ig/TCR rearrangements: an effective method to predict relapse in children with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

Victoria A. Lavrinenko 1, Alexandr N. Meleshko 1, Dmitry V. Lutskovich 1, Yulia E. Mareiko 1, Dmitriy V. Prudnikov 1, Mikhail V. Belevtsev 1, Olga V. Aleyinkova 1, Ildar M. Barkhatov 2, Boris V. Afanasyev 2

1 The Republican Research and Practical Center of Pediatric Oncology, Hematology and Immunology, Minsk, Republic of Belarus
2 R. Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation at the First St. Petersburg State I. Pavlov Medical University, St. Petersburg, Russian Federation

Dr. Viktoria A. Lavrinenko, The Republican Research and Practical Center of Pediatric Oncology, Hematology and Immunology, Borovlany, Frunzenskaya St. 43, 223053, Minsky District, Minsk, Republic of Belarus

E-mail: lavrinenkovictoria@gmail.com

Citation: Lavrinenko VA, Meleshko AN, Lutskovich DV et al. Minimal residual disease monitoring by RQ-PCR of Ig/TCR rearrangements: an effective method to predict relapse in children with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Cell Ther Transplant 2018; 7(4): 47-60

Summary

At the present time, clinical relapses remain the major cause of treatment failure in children with acute lymphoblastic leukemia (ALL) treated by allogeneic hematopoietic stem cell transplantation (allo-HSCT). So far, the requirements for precise quantification of minimal residual disease (MRD) after HSCT were not confirmed. The aim of this study was to evaluate the impact of MRD assays on management and prediction of outcomes after allo-HSCT.

Patients and methods

The Ig/TCR markers were identified for MRD monitoring in 37 (82.2%) of 45 patients. Presence of high-level MRD after allo-HSCT was an unfavorable prognostic factor for the clinical outcome. The 3-year cumulative incidence (CI) of relapse in the patients with negative MRD vs MRD levels of ≤10⁻³, and >10⁻³ proved to be 10.7±7.4%; 14.6±14.6%, and 100%, respectively (p<0.0001). Event-free survival (EFS) was 66.6±11.4% vs 43.8±18.8% vs 0% (p=0.0012) at the respective MRD levels, whereas overall survival (OS) was 83.6±8.8% vs 57.1±18.7% vs 0% (p=0.0083), resp., for undetectable, ≤10⁻³, and >10⁻³ MRD levels. MRD positivity combined with increasing mixed chimerism (MC) was followed by relapse in almost all cases. MRD clearance was more often observed in patients with full donor chimerism (FDC) having graft-versus-host disease (GvHD) post-transplant, or after donor lymphocyte infusion.

Conclusion

Positive MRD after HSCT is an unfavorable factor for OS and EFS, being associated with ALL re-occurrence. We identified the high-risk group for relapses after allo-HSCT among ALL patients, i.e., those cases which showed MRD positivity with mixed chimerism (MC) and absence of GvHD, and/or had MRD>10⁻³.

Keywords

Acute lymphoblastic leukemia, hematopoietic stem cell transplantation, minimal residual disease, donor chimerism, relapse risk.
Introduction

Allo-HSCT is a well-defined treatment mode for high-risk acute lymphoblastic leukemia (ALL) [1]. However, relapse still remains the major cause of treatment failure in children with ALL, even among patients who received transplantation during hematologic remission [2-4]. High risk of relapses after allo-HSCT arises, mostly, due to selection of the patients with signs of poor clinical prognosis (refractory to chemotherapy, unfavorable cytogenetic or molecular genetic alterations) [5, 6], whereas the patients with more favorable prognosis undergo standard chemotherapy treatment [1, 7]. The relapses occur in 30-35% of patients with ALL and it is one of the most common causes of mortality after allo-HSCT [2, 3, 8]. Survival of patients who experienced relapse is about 3-19% depending on the time between allo-HSCT and relapse [9]. In the case of clinical posttransplant relapse further treatment options are limited and often ineffective [10, 11]. For example, a second allo-HSCT can give a chance to cure such patients, but it is associated with high morbidity and mortality. Donor lymphocyte infusion (DLI) has a limited success if it is started during hematological relapse [12]. At the same time, immunotherapy at the stage of early relapse (before hematological manifestation), when the leukemia clone is still small, is more effective than relapse treatment [12-15]. Therefore, the study of early signs of disease recurrence is particularly important.

The early signs of impending ALL relapse after allo-HSCT are usually detected by MRD monitoring using the following means: 1) flow cytometry of leukemia-associated immunophenotype, or quantitative real-time PCR of chimeric oncogenes, or clonal rearrangements of immunoglobulin molecules, or T-cell receptor genes (Ig/TCR-PCR) [16-18]; 2) donor chimerism monitoring [19, 20].

A clone of ALL cells originating from a single primary-transformed cell carries identical Ig/TCR rearrangements in all the malignant cells. Therefore, the rearrangements detected in ALL samples at diagnosis could serve as specific molecular markers for MRD monitoring. Ig/TCR rearrangements allow MRD monitoring in the vast majority of ALL patients, and comparing the results after allo-HSCT [21].

MRD monitoring in pediatric ALL by Ig/TCR rearrangements has widely been accepted as a reliable prognostic factor of relapse during chemotherapy and before allo-HSCT [1]. However, its application after allo-HSCT has been less clearly defined and still controversial. The significance of precise quantification of MRD after transplantation is not completely established. The aim of the study was to evaluate the impact of quantitative MRD on outcomes of allo-HSCT.

Patients and methods

Our study included 45 patients with ALL or biphenotypic AL who underwent the first allo-HSCT at the Center for Pediatric Oncology, Hematology and Immunology from 2010 to 2017. Initial screening for Ig/TCR clonal rearrangements was performed in all the patients. MRD monitoring using Ig/TCR targets was performed in 35 of them (eight patients had no target markers, 1 had no primary engraftment, no sample material was obtained after 1 alloHSCT). Basic characteristics of 35 patients with ALL/biphenotypic AL enrolled in the posttransplant MRD studies are listed in Table 1. The recipient age at the time of transplantation was 2-25 (median 11) years. All parents or guardians signed the informed consent. All the patients received myeloablative conditioning (MAC), except of one with Nijmegen syndrome/ALL who underwent a reduced-intensity conditioning regimen (RIC).

Table 1. Characteristics of patients with ALL and biphenotypic AL (n= 35) included in the MRD study after allo-HSCT

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recipient age, median (range), years</td>
<td>11 (2-25)</td>
</tr>
<tr>
<td>Donor age, median (range), years*</td>
<td>27 (1-48)</td>
</tr>
<tr>
<td>Recipient gender: male/female, n (%)</td>
<td>23/12 (66%/34%)</td>
</tr>
<tr>
<td>Donor: male/female, n (%)</td>
<td>23/12 (66%/34%)</td>
</tr>
<tr>
<td>Diagnosis, n (%)</td>
<td>ALL</td>
</tr>
<tr>
<td></td>
<td>CR1</td>
</tr>
<tr>
<td></td>
<td>CR2</td>
</tr>
<tr>
<td></td>
<td>CR&gt;3</td>
</tr>
<tr>
<td></td>
<td>non-remission</td>
</tr>
<tr>
<td>Nijmegen syndrome / ALL, CRI</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>biphenotypic AL, CRI</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Donor type, n (%)</td>
<td>MSD</td>
</tr>
<tr>
<td></td>
<td>MUD</td>
</tr>
<tr>
<td></td>
<td>MMFD</td>
</tr>
<tr>
<td></td>
<td>MMUD</td>
</tr>
<tr>
<td>Stem cell source, n (%)</td>
<td>Bone marrow</td>
</tr>
<tr>
<td></td>
<td>Peripheral blood stem cells</td>
</tr>
<tr>
<td>Conditioning</td>
<td>MAC based on total body irradiation</td>
</tr>
<tr>
<td></td>
<td>MAC based on busulfan/treosulfan</td>
</tr>
<tr>
<td></td>
<td>MAC, others</td>
</tr>
<tr>
<td></td>
<td>RIC</td>
</tr>
<tr>
<td>Cell dose, median (range), ×10^6/kg</td>
<td>4.3 (1.4-14.4)</td>
</tr>
<tr>
<td>CD34+ cell dose, median (range), ×10^6/kg</td>
<td>4.8 (0.2-16.9)</td>
</tr>
<tr>
<td>T-depletion, n (%)</td>
<td>5 (14%)</td>
</tr>
<tr>
<td>GvHD prophylactic, n (%)</td>
<td>CNI</td>
</tr>
<tr>
<td></td>
<td>CNI+ MTX</td>
</tr>
<tr>
<td></td>
<td>CNI+ MMF</td>
</tr>
<tr>
<td></td>
<td>MMF</td>
</tr>
</tbody>
</table>

For MRD assays, bone marrow (BM) and peripheral blood (PB) samples were collected on days +30, +60, +100, +180, +365 after alloHSCT, and every six months thereaft er. Mononuclear BM cells were isolated in the Histopaque density gradient (Sigma-Aldrich, USA). DNA extraction was carried out by phenol-chloroform method. DNA quality and concentration was evaluated with a NanoDrop 2000c spectrophotometer (ThermoFisher Scientific, USA).

Genomic DNA samples at diagnosis were screened by PCR for clonal IgH, IgK immunoglobulin and rearrangements of TCRD, TCRG, TCRB genes. DNA amplification was performed with primers, recommended by BIOMED-1 Concerted Action [22] for IgK and TCRG genes, and a report by Chim et al. for IgH gene [23]. The TCRD gene was amplified...
Allele-specific oligonucleotides (ASO) primers were select-
in ALL was reported in our previous publications [25, 26].

The detection procedure of different Ig/TCR rearrangements in ALL was published in our previous publications [27]. For MRD quantification, we prepared serial ten-fold dilutions of diagnostic DNA in polyclonal controls to make a standard curve construction. To normalize the individual results, the same samples were amplified with primers for albumin reference gene [28]. A standard curve for the albumin gene was plotted with diagnostic DNA serially diluted in water. Standard Quantity (SQ, mean of triplicate) was automatically generated by CFX96 based on standard curve for both albumin and target. Interpretation of MRD analysis results was performed in accordance with the guidelines published by the European Study Group on MRD detection [29].

ASO-primers and germline TaqMan probe approach were applied for RQ-PCR analysis in CFX96 machine (Bio-Rad, USA). PCR amplification was performed in 20 μL reaction mix with TaqMan Universal PCR Master Mix (Applied Biosystems, USA), 500 ng of genomic DNA, 500 ng of each primer and 150 ng of fluorescent TaqMan probe labeled with 3’FAM, 5’BHQ. The panel of germline primers and probes was published elsewhere [27]. For MRD quantification, we used reagents for fixation and permeabilization (Becton Dickinson, USA) for detection of intracellular antigens. Following incubation and staining, the cells were washed once in phosphate buffer saline with subsequent fixation in 1% paraformaldehyde. FC-analysis was carried out on the Navios flow cytometer (Beckman Coulter, USA) using the CXP program.

Donor chimerism was determined by real-time PCR of InDel markers and multiplex PCR of short tandem repeats (STR) in BM and/or PB on +30, +45, +60, +80, +100, +140, +180, +245, + 365 days after allo-HSCT and, thereafter, every six months. In case of mixed chimerism (MC), the studies were conducted more often. AmpFLISTR® SGM Plus® PCR Amplification Kit (ABI, UK) was used for amplification of STR markers, PCR products were separated by capillary electrophoresis using 3130 Genetic Analyzer (Applied Biosystems, USA). Distinct alleles were identified by means of GeneMapper software (Applied Biosystems, USA). InDel-PCR was performed as previously described [30-32]. Full donor chi-
merism (FDC) was defined as >99% donor cells, and mixed chimerism was accepted at 5-99% donor cells.

Statistical evaluation was performed by non-parametric methods using the STATISTICA approach. Overall sur-
vival was defined as the time period between allo-HSCT and death, or to the last observation date. Treatment-
related mortality (TRM) was defined as a death in complete remission state (CR) without preceding relapse, from any causes associated with HSCT procedure. Event-free surviv-
al (EFS) was determined as survival without TRM, relapse, rejection, or secondary tumor. The time to clinical events (relapse, TRM, GVHD) was determined from the date of alo-
loHSCT. Kaplan-Meier estimates were performed to predict probabilities for overall survival and EFS [33]. The log-rank test was used for comparisons. Cumulative incidence (CI) curves were calculated to assess incidence of relapse (CIR) and TRM [34]. Gray's test was used for comparisons of CIs [35]. Fisher's exact test was applied in order to compare the patients' categorical data. The results of statistical evaluation were considered significant at p<0.05.

Results

Survival of patients with different MRD status after allo-HSCT

Ig/TCR clonal rearrangements were identified for 37 of 45 patients (82.2%). Chimeric onco-
genets TEL-AML1, BCR-ABL1, MLL1-AF4 was performed by quantitative real-time PCR of the cDNA. The real-time PCR was performed in 25-μL volume containing 2x TaqMan Universal PCR Master Mix (Applied Biosystems, USA), 300 nM primers, 200 nM TaqMan probes and 5 μL of cDNA or standards. Commercial standards (Qiagen, Germany) were used for calibration of absolute gene copy numbers. The PCR conditions were as follows: 2 min, 50°C; 10 min, 95°C; 50 cycles (95°C, 15 sec; 60°C, 60 sec).

MRD detection was also performed by multiparametric flow cytometry (FC) of mononuclear cell suspensions (1 million cells/mL, 100 μL). A panel of monoclonal antibodies conjugated with fluorescent labels FITC, PE, PC5, PC7 (Beckman Coulter, USA). In addition, we used reagents for fixation and permeabilization (Becton Dickinson, USA) for detection of intracellular antigens. Following incubation and staining, the cells were washed once in phosphate buffer saline with subsequent fixation in 1% paraformaldehyde. FC-analysis was carried out with the Navios flow cytometer (Beck-
man Coulter, USA) using the CXP program.

In all six patients who reached high MRD levels (>10^{-3}), we observed recurrence of the disease. Only one (16.7%) pa-
tient relapsed of six children with intermediate MRD lev-
els (10^{-4}-10^{-3}). Two patients with MDR level <10^{-4} retained their CR state. Generally, in cases of positive MRD, the pa-
tients with relapse showed higher levels of preceding MRD (1.6*10^{-2}-2.7*10^{-2}), than the relapse-free patients (<10^{-4}-10^{-5}),
as seen from Table 2. The three-year cumulative incidence (CI) of relapse for the patients with non-detectable MRD, with MRD ≤10^{-3}, and >10^{-3} was, respectively, 10.7±7.4% vs 14.6±14.6% vs 100% (p<0.0001). Overall survival rates (OS) were 83.6±8.8% vs 57.1±18.7% vs 0% (p=0.0083), and EFS rates were 66.6±11.4% vs 43.8±18.8% vs 0% (p=0.0012), respectively (Fig. 2).

In two patients, positive MRD was not found in BM cells before relapse. One patient had extramedullary relapse (EMR) in the central nervous system (CNS). In the second patient, a loss of Ig/TCR target was observed in hematological BM relapse.

MRD monitoring with Ig/TCR rearrangements in BM, along with PB, was performed in 10 patients. In seven cases (70%), positive MRD was detected before relapse in both BM and PB. In three patients, MRD was detected in BM only, one of them relapsed. In this patient, MRD was still not detected in PB at the time of relapse.

Comparison of MRD results obtained by different targets/methods

In nine patients, MRD was monitored by Ig/TCR rearrangements as well as expression of BCR-ABL1 (n=4), MLL-AF4 (n=4), TEL-AML1 (n=1). In only one case, the results were
### Table 2. Time dynamics of MDR in patients with ALL

<table>
<thead>
<tr>
<th>Patient</th>
<th>MRD level</th>
<th>MRD increase</th>
<th>MRD clearance</th>
<th>DLI</th>
<th>aGvHD/cGvHD (grade)</th>
<th>Chimerism</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>&lt;10^{-4}–10^{-3}</td>
<td>yes; from +30 (** to +60 day per Ig (***)</td>
<td>yes, after +100 day</td>
<td>no</td>
<td>3/no</td>
<td>Decreasing MC/FDC</td>
<td>alive (5 years)</td>
</tr>
<tr>
<td>2</td>
<td>&lt;10^{-4}–4*10^{-4}</td>
<td>yes; negative on +30 day, from +60 day growth up to 4*10^{-4} on +100 day (**)</td>
<td>yes, after +150 day</td>
<td>no</td>
<td>4/ext</td>
<td>FDC</td>
<td>TRM (165 day)</td>
</tr>
<tr>
<td>3</td>
<td>10^{-4}–10^{-3}</td>
<td>yes; negative on +30 day, from +60 day growth up to 10^{-4} on +100 day (**)</td>
<td>yes, after +100 day</td>
<td>no</td>
<td>3/ext</td>
<td>FDC</td>
<td>alive (3.7 years)</td>
</tr>
<tr>
<td>4</td>
<td>2.2*10^{-4}</td>
<td>1 point</td>
<td>-</td>
<td>no</td>
<td>1</td>
<td>FDC</td>
<td>alive (95 days)</td>
</tr>
<tr>
<td>5</td>
<td>&lt;10^{-5} after rejection</td>
<td>positive on +30–40 day (&lt;10^{-4}); MRD clearance, rejection; MRD reappearance (2.25*10^{-5}–10^{-4}) on +519–736 days</td>
<td>yes, after +60 day; after +839 day</td>
<td>no</td>
<td>no</td>
<td>Increasing MC/0%</td>
<td>alive (5 years), rejection on +74 day</td>
</tr>
<tr>
<td>6</td>
<td>&lt;10^{-4}–4*10^{-4}</td>
<td>yes; negative on +30 day, from +60 day growth and persistence of MRD</td>
<td>temporary after DLI</td>
<td>yes</td>
<td>no/no</td>
<td>FDC</td>
<td>TRM (332 day)</td>
</tr>
<tr>
<td>7</td>
<td>&lt;10^{-4}</td>
<td>yes; negative on +30 day, positive on +60 days (&lt;10^{-4}); DLI, clearance</td>
<td>yes, after DLI</td>
<td>yes</td>
<td>no/no</td>
<td>FDC</td>
<td>alive (341 days)</td>
</tr>
<tr>
<td>8</td>
<td>2.7*10^{-2}</td>
<td>1 point before relapse</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>Increasing MC</td>
<td>BM relapse (66 day); death (221 day)</td>
</tr>
<tr>
<td>9</td>
<td>2.2*10^{-2}</td>
<td>1 point before relapse</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>MC (1 point)</td>
<td>BM relapse (54 day); death (109 day)</td>
</tr>
<tr>
<td>10</td>
<td>1.2<em>10^{-5}–3</em>10^{-3}</td>
<td>yes; decrease and clearance of MRD after IDL; then increase up to 2*10^{-3}</td>
<td>temporary after DLI</td>
<td>yes</td>
<td>after DLI</td>
<td>Increasing MC (temporary FDC after DLI)</td>
<td>BM relapse (368 day); death (671 day)</td>
</tr>
<tr>
<td>11</td>
<td>2<em>10^{-4}–2.7</em>10^{-4}</td>
<td>yes; positive on +30 day, negative on +47 and +82 days, positive on +93 day</td>
<td>temporary</td>
<td>no</td>
<td>no</td>
<td>Increasing MC</td>
<td>BM relapse (124 day); death (184 day)</td>
</tr>
<tr>
<td>12</td>
<td>1.8<em>10^{-5}–2.9</em>10^{-3}</td>
<td>yes; negative till +123 day, MRD growth with unclear dynamics (positive and negative points)</td>
<td>temporary after DLI</td>
<td>yes</td>
<td>after DLI</td>
<td>FDC</td>
<td>BM relapse (552 day); lost follow up</td>
</tr>
<tr>
<td>13</td>
<td>10^{-3}–1.6*10^{-1}</td>
<td>yes; positive on +30 day, negative +60 day, then MRD growth</td>
<td>temporary</td>
<td>no</td>
<td>no/no</td>
<td>FDC</td>
<td>BM relapse (226 day); death (384 day)</td>
</tr>
<tr>
<td>14</td>
<td>10^{-2}</td>
<td>1 point (on +30 day)</td>
<td>-</td>
<td>no</td>
<td>no/no</td>
<td>Increasing MC</td>
<td>BM relapse (365 day); death (419 day)</td>
</tr>
</tbody>
</table>

(•••) – on the background of GvHD
(••••) – after GvHD
MRD measured by immunophenotyping and Ig/TCR rearrangements was monitored in four patients in parallel (at the same time points after HSCT). Negative MRD was detected by both methods in one patient. In three patients, we received discordant results: there were positive MRD values of <10⁻³ detected by Ig/TCR gene rearrangements, however, being negative by immunophenotyping technique. Nevertheless, negative results were observed in some cases by both methods.

Comparison of MRD data obtained by Ig/TCR and chimerism markers

Donor chimerism monitoring was performed in all 35 patients.

1) Full donor chimerism (FDC) and negative MRD state were detected in 19 patients, only 2 of them have relapsed (Table 3). In one patient with loss of Ig/TCR target, a relapse was diagnosed more than 2 months after last chimerism monitoring in BM cells (D+377, late isolated BM relapse). The second patient with extramedullary CNS relapse had negative MRD and FDC in PB and BM cells, even at the time of relapse.

2) Mixed chimerism (MC) and negative MRD were detectable in 2 cases. One patient had negative MRD and MC (98.9%) in BM on D+30. This patient reached FDC (since +60 day), but died with infectious complications on D+542. The second patient showed FDC conversion to increasing MC accompanied by infection, and died on D+78.

3) FDC and positive MRD (up to 1.6×10⁻¹) was observed in 7 patients, two of them have relapsed. The patient №12 had BM relapse on D+522, with last testing point at D+347, when full donor chimerism and MRD of 5×10⁻⁵ were determined. In the second patient (№13), a BM relapse was diagnosed by the D+226. Slightly decreased chimerism level of 99.1% was registered in blood leukocytes, along with increased MRD level to 15% at the last term before the relapse (D+197). In three patients with FDC, we observed MRD clearance, the rest of them retained their MRD positivity at the last examination.
4) *MC and positive MRD* was traced in seven patients, five of them had the disease recurrence. Before relapse, an increase of MC and MRD up to $2.2 \times 10^{-2}$ was observed in four patients (the fifth patient had an early relapse, and only one monitoring point before relapse). Patient №5 with increasing MC has shown graft rejection on D +74 with subsequent autorecovery without ALL reoccurrence, with MRD levels in BM of $<10^4$ on days +27 to +39, then becoming negative at later terms. Patient №1 had an MC state (98.5% on D+30 in BM and PC) with FDC state achieved by the D +60; this patient is now alive, being in complete remission.

Thus, we have revealed sufficient concordance between MRD and donor chimerism in 26 (74.3%) out of 35 cases. The most favorable group comprised a subgroup with negative MRD and FDC, an intermediate group consisted of patients with positive MRD and FDC, and the most unfavorable group included the patients with positive MRD and increasing MC. The respective 3-year CI of relapse for these groups were as follows: $11.9 \pm 8.2\%$ vs $41.7 \pm 29.5\%$ vs $80.0 \pm 23.9\%$ ($p<0.0008$); the OS values were $94.4 \pm 5.4\%$ vs $44.4 \pm 22.2\%$ vs $20.0 \pm 17.9\%$ ($p=0.0029$); EFS probability was $75.0 \pm 11.0\%$ vs $25.0 \pm 20.4\%$ vs $0\%$ ($p<0.0001$), respectively (Fig. 4).

**Dependence of survival upon MRD and GVHD association**

Grade I-IV acute GvHD (aGvHD) was observed in 17 (48.6%) of 35 patients, and six of them were diagnosed with severe aGvHD (grade III-IV). MRD-negative state was registered more often in the patients with aGvHD (in 13 of 17 cases), as compared to the GvHD-free cases (8 of 18 patients, $p=0.085$).

1) Among 13 patients with *negative MRD and aGvHD*, only 1 (7.7%) patient had relapse in CNS.

2) Among eight patients with *negative MRD without aGvHD*, nobody has relapsed.

3) None of the four patients with *positive MRD and aGvHD* relapsed. MRD clearance occurred in 4 patients (40%) on the days $+100--+150$.

4) In seven (70%) of 10 patients with *positive MRD without aGvHD* disease reoccurred. Four of these 10 patients received DLI, 2 of them experienced relapse despite GvHD signs observed after IDL.

Clinical outcomes of the patients with negative MRD without aGvHD, patients with negative MRD with aGvHD, and patients with positive MRD and aGvHD were nearly similar, being definitely better than in the group of aGvHD-free patients with positive MRD. The three-year CI of relapse rates were as follows: $20.0 \pm 20.0\%$ vs $7.7 \pm 7.7\%$ vs $0\%$ vs $80.0 \pm 20.2\%$ ($p=0.0008$). The respective, overall survival probability was $80.0 \pm 17.9\%$ vs $84.6 \pm 10.0\%$ vs $66.7 \pm 27.2\%$ vs $18.0 \pm 15.1\%$ ($p=0.026$). The EFS values for these subgroups were: $60.1 \pm 21.9\%$ vs $67.3 \pm 13.6\%$ vs $66.7 \pm 27.2\%$ vs $0\%$ ($p=0.0004$), respectively (Fig. 5).

**Discussion**

The MRD monitoring can help to identify presence of tumor cells that survived after the conditioning. However, this
assay is applicable only for patients with a defined marker (chimeric oncogenes, mutations, Ig/TCR rearrangements or leukemia-associated immunophenotype). Identification of tumor-specific mutations is the most accurate diagnostic approach showing high specificity. However, the structure of these mutations should be suitable for MRD monitoring, with a sensitivity of, at least, $10^{-4}$ [36]. In ALL monitoring, quantitative real-time PCR (qPCR) allows to determine MRD by specific chimeric oncogenes/transcripts, point mutations and other rearrangements, such as BCR-ABL1, PML/RARA, RUNX1-RUNX1T1 (AML1-ETO), CBFB-MYH11, MLL translocations, at a high sensitivity of $10^{-3}$-$10^{-4}$ [37]. Chimeric oncogenes are detected only in a small number of patients with ALL [36, 38]. In our study, they were found only in 11% of transplantation patients. There exists another alternative to chimeric oncogenes and mutations in ALL, i.e., clonal rearrangements of Ig and TCR genes, which are an attractive marker for MRD monitoring, being detectable in vast majority of ALL patients (up to 90-95% [36, 37], 82% of our patients).

Analytical sensitivity is an important aspect of MRD assay, since an arising leukemic clone posttransplant is regarded as an unfavorable event. MRD monitoring with Ig/TCR has a good sensitivity up to $10^{-4}$-$10^{-5}$. Measurement of chimeric oncogene expression may be an even more sensitive approach in some cases, since a single malignant cell may contain several dozens or even thousands copies of chimeric oncogenes. It increases sensitivity up to 1 Ig+/+, thus allowing earlier detection of tumor cells after allo-HSCT than with DNA-targets. However, the predictive value of individual methods and expression markers is not well defined. By contrast, MRD monitoring procedure with Ig/TCR rearrangements has been standardized and provides comparable results obtained from different patients, which makes it possible to assess not only the presence of MDR after allo-HSCT, but also takes its levels into account [4, 36, 37, 39]. Immunophenotyping using flow cytometry has a lower sensitivity (up to $10^{-4}$) than PCR-based methods. Its application for MRD monitoring after allo-HSCT is limited due to difficulties with interpretation of results [40]. Bone marrow regeneration after allo-HSCT makes it difficult to identify leukemic cells on the background of normal lymphoid precursors [1].

It is also necessary to consider the stability of various MRD markers [36]. In rare cases, the Ig/TCR target can be lost due to somatic mutations accumulating in tumor cells [41, 42], what we have found in one case (2.9% of total group).

RQ-PCR measuring of Ig/TCR rearrangements provides suitable sensitivity and specificity, being, however, complicated by high costs of the assay, delayed purchasing of ASO, and loss of a gene target in rare cases. However, this method has been accepted in Europe as a standard approach to MRD monitoring [1].

Chimerism assays are used for assessing donor cell engraftment, but they also can be applied for relapse prediction. The study of chimerism by InDel-PCR has a sensitivity of $10^{-4}$ [30, 32], but up to 1% of the recipient cells, even after myeloablative conditioning, may be normally present in BM and PB after allo-HSCT [43, 44]. Therefore, the sensitivity of donor chimerism for prediction of relapses is limited to $10^{-5}$. 

Figure 5. Probability of relapse (A), OS (B) and EFS (C) in patients with ALL/biphenotypic AL according to MRD and chimerism after allo-HSCT. Curves are designated black (MRD-/no GVHD); blue (MRD-/aGVHD); red (MRD+/no aGVHD); or green (MRD+/aGVHD)
In addition, the chimerism monitoring is a non-specific method, since the persistent residual cells of recipient origin can be either normal hematopoietic or malignant cells, or both.

MRD monitoring allows identifying the ALL patients being at high risk for relapses after allo-HSCT. It was shown in all patients that the level of MRD before transplantation significantly affects the result of posttransplant outcome [4, 40, 45-52]. Not all patients with negative MRD pre-transplant remain relapse-free at later terms, as well as not all patients with positive MRD relapse after HSCT. Therefore, the measurement of MRD post-HSCT is another powerful tool, with a potential for more precise relapse prediction. A limited number of trials has explored the role of MRD assays in the post-HSCT period [1]. Post-HSCT positive MRD strongly associated with high risk of relapse and low survival in childhood ALL [4, 40, 50, 52–55]. The presence of detectable MRD after transplant was independent of other factors, including pre-HCT MRD and aGVHD status [40].

In our study, the presence of MRD after allo-HSCT significantly increased the probability of disease recurrence and led to poor overall and event-free survival. We showed that the risk of relapse was increased only in the patients with high MRD levels (>10^-3, CI of relapse is 100%), whereas risk of relapse did not differ for the patients with MRD ≤10^-3 and with negative MRD, (CI of relapse 11% and 15% accordingly). Similarly, Balduzzi et al. have shown that the patients who had high MRD >10^-3 at any time point post-HSCT, did relapse, despite any attempts to prevent the recurrence of disease [54]. Most patients relapsed with MRD level of >10^-3, but the patients with MRD <10^-3 to 10^-4 were more likely to clear their leukemia cells [52, 54, 56]. By contrast, the study of Bader et al. [53] has shown that any level of MRD after allo-HSCT did increase risk of relapse, even MRD <10^-4, if compared to MRD-negative patients on D+60, +90 and +180, but not on +30 days, and the same results were reported by Zhao group [55]. However, our data and results from other authors [52-54, 56] suggest that the patients with low post-transplant MRD levels <10^-3-10^-4 do not necessarily relapse, and additional risk stratification is needed.

Despite recommendations on monitoring of MRD and chimerism for relapse prediction of ALL after allo-HSCT, there are only few studies comparing these two methods [20, 56, 57], and the results of these studies do not give a complete answer as to how a combination of these approaches can improve relapse prediction. We have obtained concordant results between MRD and chimerism in 74% cases. Standard methods for determining MPD are of >1lg, more sensitive, than the methods for chimerism detection. The main difference between these two approaches is that MRD monitoring directly determines the residual tumor cells and the chimerism analysis gives only information about the persistence/ recovery of autologous hematopoiesis. Reappearance of recipient cells may indicate the establishment of immunological tolerance thus potentially leading to a weaker immunological surveillance of malignant cells and the development of relapse [58]. Rarely, stable mixed chimerism in some patients with malignant diseases may persist for up to 20 years after alloHSCT, and it does not lead to relapse or rejection [59], although this is rather an exception to the rules. In the majority of cases, the onset of increasing mixed chimerism precedes disease recurrence [19, 20, 32, 60-62].

In our study, a combination of these two diagnostic approaches makes it possible to stratify patients into groups of high, intermediate and low risk of relapse with a very high accuracy. The most favorable group was presented by the patients with negative MRD and FDC with a good OS (94%) and EFS (75%), and a low incidence of relapse (12%). The presence of MRD combined with increasing MC led to the development of relapses in almost all patients (CI relapse 80%) and significantly worse OS (20%) and EFS (0%). In the presence of FDC, some patients showed MRD clearance and became MRD-negative, but this group of patients still had relatively high risk of relapse (CI relapses 42%) and intermediate OS (44%) and EFS values (25%). Patients could clear their MRD by an immunologic graft-versus-leukemia (GvL) effect, but MRD must be cleared until the establishment of graft tolerance towards the recipient; otherwise, uncontrolled proliferation of residual leukemia cell finally results in hematological relapse [54]. The patients with positive MRD in late posttransplant period are shown to relapse more readily, when compared to patients with MRD positivity over the first 1-2 months [53-56]. During the initial phase after allo-HSCT (within the first 2 months), immunologic reconstruction is incomplete, and GvL effect is not fully exhibited [55]. Our study also confirms the theory of immunological tolerance, because MRD clearance was more often observed in patients with FDC and GvHD, or after DLI. None of the patients with positive MRD developed bone marrow relapse in the presence of GvHD, in contrast to patients with no GVHD (CI relapse 80%). The role of the GvL effect is supported by studies showing that the ALL patients who experience GvHD have a lower risk of relapse [40, 49, 56]. As a rule, these three parameters (MRD, GVHD and chimerism) are interrelated. Detection of MC was often combined with positive MRD and lack of GVHD. Absence or reduction of MRD was observed in the patients with FDC and GVHD development.

We have shown that the combination of MRD and chimerism monitoring allows stratification of ALL patients into the groups of relapse risk. In contrast to previous studies [54, 56], we were able to find out prognostic value of increasing MC due to application of sensitive PCR-based method of chimerism detection and testing of BM samples, along with PB cells. Our study demonstrates the combined effect of MRD, chimerism and GVHD on the outcomes in allo-HSCT patients.

A serious issue is associated with development of extramedullary relapses which are underdiagnosed because they can manifest with no detectable MRD and in FDC state in the presence of GVHD, even in relapse burden [56, 63]. There is also a risk to miss early signs of relapse, if the monitoring intervals for the marrow chimerism and MRD exceed 2 months. We recommend monitoring BM at least once or twice a month over first 6-12 months after alloHSCT, when the risk of relapse is high, especially for the patients with previous positive MRD and/or MC, and absence of GVHD signs.

Like other workers, we observed that, in patients with MRD level of <10^-3, the clearance of malignant clone can be
achieved with preventive immunotherapy [54, 64]. In view of these considerations, MRD combined with chimerism could be used as a tool to guide posttransplant pre-emptive immunomodulation or immunotherapy, in order to prevent a disease relapse.

**Conclusion**

The presence of positive MRD after allo-HSCT is known to be an unfavorable prognostic factor associated with relapses, poor overall and decreased event-free survival. In patients with ALL, the presence of MRD after allo-HSCT is not always associated with development of relapses. The manifestation of the GvL effect can be observed in patients with FDC and GvHD or after DLI. The patients of a high-risk group for relapse include those with high MRD level >10⁻³, as well as the patients in whom the presence of MRD is combined with increasing mixed chimerism and/or absence of GVHD. Monitoring of MRD in bone marrow does not always allow us to detect extramedullary relapses.

**Acknowledgements**

The authors report no conflicts of interest.

**References**


55. Zhao XS, Liu YR, Zhu HH, Xu LP, Liu DH, Liu KY, Huang XJ. Monitoring MRD with flow cytometry: an effec-


Мониторинг минимальной остаточной болезни путем RQ-ПЦР перестроек Ig/TCR – эффективный метод прогноза рецидивов у детей с острым лимфобластным лейкозом после аллогенной трансплантации гемопоэтических стволовых клеток

Виктория А. Лавриненко 1, Александр Н. Мелешко 1, Дмитрий В. Луцкович 1, Юлия Е. Марейко 1, Дмитрий В. Прудников 1, Михаил В. Белевцев 1, Ольга В. Алейникова 1, Ильдар М. Бархатов 2, Борис В. Афанасьев 2
1 Республика научно-практический центр детской онкологии, гематологии и иммунологии, Минск, Республика Беларусь
2 НИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой Первого Санкт-Петербургского государственного медицинского университета им. И. П. Павлова, Санкт-Петербург, Российская Федерация

Резюме

Клинические рецидивы остаются основной причиной неудач в лечении детей с острым лимфобластным лейкозом (ОЛЛ) после аллогенной трансплантации гемопоэтических клеток (алло-ТГСК). К настоящему времени не подтверждена необходимость точной количественной оценки минимальной остаточной болезни (МОБ) после трансплантации. Целью настоящего исследования была оценка вклада диагностики МОБ в тактику лечения и исходы алло-ТГСК.

Пациенты и методы

Для мониторинга МОБ идентифицировали маркеры Ig/TCR у 37 из 45 больных (82,2%). Наличие МОБ высокой степени после алло-ТГСК было неблагоприятным прогностическим фактором для клинического исхода. Трехлетняя кумулятивная встречаемость (СИ) рецидива заболевания в группах пациентов с негативными результатами оценки МОБ, уровнями МОБ ≤10⁻³ и >10⁻³ была, соответственно, 10,7 ± 7,4%; 14,6 ± 14,6%, и 100% (p<0,0001). Бессобытийная выживаемость (EFS) при этом составила 66,6 ± 11,4% против 43,8 ± 12,8% и 0%, соответственно (p=0,0012), тогда как общая выживаемость (ОВ) была 83,6 ± 8,8%, по сравнению с 57,1 ± 18,7% и 0% (p=0,0083) для групп с отсутствием МОБ, при ее уровнях ≤10⁻³ и >10⁻³. Наличие МОБ в сочетании с повышением уровней смешанного химеризма (СХ) сопровождалась рецидивами почти во всех случаях. Падение уровней МОБ наиболее часто отмечалось у пациентов с полным донорским химеризмом при наличии реакции «трансплантат против хозяина» (oРТПХ) или после переливания донорских лимфоцитов.

Выводы

Наличие МОБ после ТГСК является фактором неблагоприятного исхода по параметрам общей и бессобытийной выживаемости и ассоциировано с рецидивом ОЛЛ. Мы идентифицировали группу высокого риска рецидивов после алло-ТГСК среди больных ОЛЛ, а именно – пациентов с наличием МОБ и смешанного химеризма и отсутствием РТПХ, и/или больных с уровнями МОБ выше 10⁻³.

Ключевые слова

Острый лимфобластный лейкоз, трансплантации гемопоэтических стволовых клеток, минимальная остаточная болезнь, донорский химеризм, риск рецидивов.